Anebulo Pharmaceuticals, INC 8-K filings

Anebulo Pharmaceuticals announced its decision to voluntarily delist from Nasdaq and deregister with the SEC, citing high costs, while reporting Q2 FY26 financial results.

Anebulo Pharmaceuticals, Inc. announced its board approved the voluntary delisting of its common stock from Nasdaq and subsequent deregistration with the SEC to suspend reporting obligations.

Anebulo Pharmaceuticals announced the final results of its tender offer, repurchasing 300,000 shares at $3.50 each for approximately $1.05 million.

Anebulo Pharmaceuticals announced preliminary results of its oversubscribed tender offer to repurchase 300,000 shares of common stock at $3.50 per share.

Anebulo Pharmaceuticals announces a cash tender offer to buy back 300,000 shares at $3.50 each, abandoning a costly reverse stock split as part of its plan to go private.

Anebulo Pharmaceuticals announced its first quarter fiscal year 2026 financial results and provided updates on its lead drug candidate, selonabant, for pediatric cannabis toxicity.

Anebulo Pharmaceuticals announced its Q4 and fiscal year 2025 financial results, highlighting a strategic pivot to an intravenous selonabant formulation for pediatric cannabis toxicity and a proposed reverse stock split for a potential going-private transaction.

Anebulo Pharmaceuticals provides an update on its proposed going private transaction and announces a review of strategic alternatives, including a potential sale or merger.

Anebulo Pharmaceuticals announced a plan to go private through a reverse stock split, offering a 91% premium to certain shareholders and delisting from Nasdaq to reduce public reporting costs.

Anebulo Pharmaceuticals is focusing on developing an intravenous formulation of selonabant for pediatric patients with cannabis-induced toxicity and reported its Q3 fiscal year 2025 financial results.

Anebulo Pharmaceuticals has regained compliance with Nasdaq Listing Rule 5635(b) after removing certain voting and transfer restrictions on shares issued in a December 2024 private placement.

Anebulo Pharmaceuticals' stockholders approved an increase in authorized shares and the declassification of the Board of Directors at the 2025 Annual Meeting.

Anebulo Pharmaceuticals' stockholders approved several key proposals at their annual meeting, including increasing the number of shares available under the 2020 Incentive Compensation Plan.

Anebulo Pharmaceuticals is addressing a Nasdaq listing deficiency related to a change of control triggered by a private placement, requiring stockholder approval to remove voting and transfer restrictions on shares held by a major stockholder.

Anebulo Pharmaceuticals reported its financial results for the quarter ended December 31, 2024, and provided updates on its clinical programs, including intravenous selonabant development and a recent stock purchase agreement.

Anebulo Pharmaceuticals announces its annual meeting of stockholders will be held on April 4, 2025, and sets deadlines for stockholder proposals and director nominations.

Anebulo Pharmaceuticals has successfully raised $15 million through a private placement and is progressing its intravenous selonabant program for pediatric cannabis toxicity.

Anebulo Pharmaceuticals reported its first quarter fiscal year 2025 financial results, highlighted by a NIDA grant and progress on its intravenous formulation of selonabant.

Anebulo Pharmaceuticals has updated its corporate presentation, which is furnished as an exhibit to a Form 8-K filing.

Anebulo Pharmaceuticals reported its fiscal year 2024 financial results, highlighting a reduction in operating expenses and progress in developing an intravenous formulation of selonabant for cannabis toxicity.

Anebulo Pharmaceuticals has been awarded a cooperative grant of up to $1.9 million from the National Institute on Drug Abuse to advance the development of an intravenous treatment for acute cannabis-induced toxicities.

Anebulo Pharmaceuticals has approved a new equity compensation policy for non-employee directors, granting them stock options upon appointment and annually.

Anebulo Pharmaceuticals is shifting its focus to developing an intravenous formulation of selonabant for treating unintentional cannabis poisoning in children, while also reporting a reduced net loss for the third quarter of fiscal year 2024.

Anebulo Pharmaceuticals announced its financial results for the quarter ended December 31, 2023, along with key business updates, including a new credit facility and progress on its lead drug candidate.